Profile of Prof Sarah Tabrizi
Sarah Tabrizi is Director of the UCL Huntington’s Disease Centre, Joint Head of Department Neurodegenerative Disease at the UCL Queen Square Institute of Neurology, a Principal Investigator at the UK Dementia Research Institute, and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery. In addition to a basic bench science programme focussing on basic cellular mechanisms of neurodegeneration in Huntington’s disease (HD) that can be harnessed for therapeutics, she also leads a large translational research programme that is working towards finding effective disease-modifying treatments for HD. She was global clinical PI on the world’s first gene silencing study for HD using anti-sense oligonucleotide therapy. The results from this trial, published in The New England Journal of Medicine in 2019, demonstrated the first antisense mediated knockdown of a toxic protein in the CNS of adults. Sarah has published over 300 peer-reviewed publications to date, has an H-index of 87, and her research work has been the subject of articles in NEJM, The Economist, Scientific American, and The Lancet. She serves on several panels including the UK HD association, the European HD Network and NINDS/NIH. Sarah was elected as a Fellow of the UK Academy of Medical Sciences in 2014. In 2017 she received the seventh Leslie Gehry Brenner Prize for Innovation in Science awarded by the Hereditary Disease Foundation. In 2018 she received the Cotzias Award from the Spanish Society of Neurology, and in 2019 the Yahr Award at the World Congress for Neurology and the Alexander Morison Medal from the Royal College of Physicians of Edinburgh.